TabsDetailsBasic DetailsDate: Tuesday, May 26, 2020Type: PublicationDescription: The objective of this manuscript was to assess the relative frequency with which oxymorphone and oxycodone (a CYP3A-metabolized opioid analgesic) were each prescribed to patients concomitantly receiving CYP3A-modifying drugs (i.e., inducers and inhibitors) to characterize opioid-prescribing patterns in patients at risk for CYP3A-related drug interactions. Read More Materials: J Manag Care Spec Pharm. 2020 May 26. doi.org/10.18553/jmcp.2020.26.5.668Additional InformationRelated Assessment(s): Concomitant Use of Opioid Analgesics and Cytochrome P450 (CYP) Inhibitors and InducersContributorsAuthor(s): D. Tyler Coyle, Tiffany S. Woodworth, David Moeny, Judy Staffa, Tamra Meyer, Corinne Woods, Emily C. Welch, Kevin Haynes, Sengwee Toh, Judith C. MaroCorresponding Author: Judith C. Maro, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.Email: judy_maro@harvardpilgrim.org
